LimmaTech Biologics AG
Better technology for better health
LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases.
In addition to our proprietary research, we also develop vaccines together with GSK.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
27.05.2026
Lilly to acquire LimmaTech Biologics for up to USD 780 million (startupticker.ch)
23.04.2025
Swiss biotechs on track to address key medical challenges (startupticker.ch)
19.03.2025
Biotech updates: A first dosing and a setback (startupticker.ch)
17.02.2025
LimmaTech secures US$6.5 million to advance vaccine against S. aureus (startupticker.ch)
21.10.2024
A new step in the clinical development (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
LimmaTech Biologics AG
Better technology for better health
Website:
lmtbio.com/
Lilly
Headquarter:
Schlieren
Foundation Date:
March 2016
Technology:
- Biotech